



**INDUSTRY
LIAISON
FORUM**



INDUSTRY
LIAISON
FORUM

ILF/Co-Infections Thematic Roundtable

The Road to HCV Eradication

Monday, 20 July 2015

18:45-21:30 PST

Vancouver, Canada



INDUSTRY
LIAISON
FORUM


The International AIDS Society



IAS 2015

vancouver, canada

8th IAS Conference on HIV Pathogenesis,
Treatment & Prevention **19-22 July 2015**



AIDS 2016

DURBAN, SOUTH AFRICA JULY 17-22, 2016



INDUSTRY
LIAISON
FORUM

The International AIDS Society

World's leading independent association of professionals working in HIV, governed by a group of international experts

Promotes the priorities of its members through strategic communications, advocacy, and global convening; these priorities are:

- Towards an HIV Cure
- Paediatric HIV (CIPHER)
- HIV Co-Infections
- Key Populations

Benefits from overarching tools:

- Journal of the International AIDS Society (JIAS)
- Industry Liaison Forum (ILF)





INDUSTRY
LIAISON
FORUM

The Industry Liaison Forum

Industry remains negatively perceived and excluded from key discussions: this impacts the response to the epidemics; the Industry Liaison Forum promotes the meaningful contribution of industry to the global response

- Mechanism to constructively engage industry and other stakeholders on issues in line with IAS Priorities





INDUSTRY
LIAISON
FORUM

The Industry Liaison Forum

The Industry Liaison Forum brings experts together during IAS 2015 to discuss:

1. Paediatric HIV diagnostics
2. The road to HCV eradication
3. The integration of HIV and other diseases

*To get involved, please contact ilf@iasociety.org
More information available online www.iasociety.org/ilf*



**INDUSTRY
LIAISON
FORUM**

The Industry Liaison Forum

ILF Industry Advisory Group members

- Gold Corporate Partners
- Silver Corporate Partners
- Bronze Corporate Partners

- Gilead Sciences
- Merck
- MSD
- ViiV Healthcare
- ViiV Healthcare

- AbbVie
- AbbVie
- Alere
- Janssen

- Abbott
- Abbott
- Cipla
- Cipla
- Female Health Company
- Omega Diagnostics
- Omega Diagnostics
- Roche Molecular Systems
- Sysmex Partec

James Rooney - USA
Sandra Lehrman - USA
Paul Schaper - USA
Manuel Gonçalves - UK
Dominic Kemps - UK

Patrick Dorr - UK
Jean van Wyk - USA
Duncan Blair - Thailand
Peter Barnes - UK

Gavin Cloherty - USA
John Hackett - USA
Denis Broun - Switzerland
Sharadd Jain - India
Denise van Dijk - The Netherlands
John Bannister - UK
Mike Iddon - UK
Ed Marins - USA
Francesco Marinucci - Germany

ILF Non-Industry Advisory Group members

- IAS Governing Council
- Regulatory / normative agencies
- Procurement / implementing organizations
- Governmental / intergovernmental organizations
- Experts in IAS Priorities or other issues
- Civil society

- Desmond Tutu HIV Foundation
- Fenway Institute
- Istituto Superiore di Sanità
- Johns Hopkins University
- Universidade Federal do Rio de Janeiro
- University of Bonn
- University of the West Indies

- U.S. Food and Drug Administration
- WHO Prequalification

- Global Fund

- UNITAID
- WHO HIV/AIDS Department

- AIGHD
- EGPAF
- Partners in Diagnostics
- Stop TB Partnership

- NEPHAK
- Treatment Action Group

Linda-Gail Bekker - South Africa
Kenneth Mayer - USA
Stefano Vella - Italy
Chris Beyrer - USA
Mauro Schechter - Brazil
Jürgen Rockstroh - Germany
Celia Christie-Samuels - Jamaica

Jeffrey Murray - USA
Lembit Rägo - Switzerland

Martin Auton - Switzerland

Philippe Duneton - Switzerland
Joseph Perriens - Switzerland

Catherine Hankins - The Netherlands
Nicholas Hellman - USA
Elliot Cowan - USA
Colleen Daniels - Switzerland

Rahab Mwaniki - Kenya
Tracy Swan - USA



Today's agenda

18:00 – 18:45	Light dinner buffet	
18:45 – 18:55	Opening words <i>Sébastien Morin (IAS, Switzerland) – ILF Research Officer</i>	
18:55 – 19:00	Introduction <i>Kenneth Mayer (Fenway Institute, USA) – ILF Co-Chair</i> <i>Jürgen Rockstroh (University of Bonn, Germany) – HIV Co-Infections Co-Chair / ILF AG member</i>	
19:00 – 19:20	Overview presentation I: <i>Highlights from the 2nd International HIV/Viral Hepatitis Co-infection Meeting</i> <i>Marina Klein (McGill University, Canada) – HIV Co-Infections Co-Chair</i>	Recent progress
19:20 – 19:40	Overview presentation II: <i>WHO Global Hepatitis Strategy – HCV epidemiology, treatment access and elimination targets</i> <i>Gottfried Hirnschall (WHO, Switzerland)</i>	WHO vision
19:40 – 20:00	Short coffee break	
20:00 – 21:15	Roundtable discussion: <i>Challenges and opportunities along the road to HCV eradication</i> <ol style="list-style-type: none"> 1. Identifying HCV-infected individuals and reaching key populations 2. Establishing treatment priorities 3. Developing new financing models (focus on middle-income countries) 4. Supporting community empowerment 5. Taking advantage of lessons learned from HIV <i>Facilitator: Paul Schaper (MSD, USA) – ILF AG member</i>	Challenges & opportunities
21:15 – 21:30	Summary and action points <i>Kenneth Mayer (Fenway Institute, USA) – ILF Co-Chair</i> <i>Jürgen Rockstroh (University of Bonn, Germany) – HIV Co-Infections Co-Chair / ILF AG member</i> <i>Sébastien Morin (IAS, Switzerland) – ILF Research Officer</i>	
21:30 – 22:30	Reception for additional informal exchanges between participants	



INDUSTRY
LIAISON
FORUM

Objectives

1. **Highlight** the most **recent progresses** regarding HCV science and access to diagnostics and treatment
2. **Provide** background **data** on the **epidemiology** of hepatitis C and current **normative guidance**
3. **Present** the **WHO vision** with regards to elimination targets towards 2030
4. **Highlight challenges** and **opportunities** as well as potential **synergies** on the road to HCV eradication
5. **Catalyze collaboration** among attendees from different types of organizations.

